CANHAEM-Hydroxyurea for Children with Sickle Cell Disease

The Sickle Cell Awareness Group of Ontario (SCAGO) is pleased with the news of CASGEVY (Exagamglogene Autotemcel) receiving marketing authorization for the treatment of Sickle Cell and Thalassemia disorders in Canada.

Pfizer Inc. announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved.

Improving the knowledge of peers and families about blood transfusion in sickle cell disease

The Role of Parents & Family Members in sickle cell disease pain management

Improving care and treatment by utilising informed decision making based on pateint preferences and best practices.